Clinical trials: sponsored by AbbVie
Healthy Volunteer, Psoriasis
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan. There will be 2 parts to this study.
- Trial name
- NCT07232004
- Testing
- ABBV-547
- Where
- 20 sites in United States, Japan
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Bipolar I Disorder, Bipolar II Disorder
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II…
- Trial name
- CANTO (NCT06605599)
- Testing
- ABBV-932
- Where
- 40 sites in United States, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Hypothyroidism
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH])…
- Trial name
- NCT06345339
- Testing
- Armour Thyroid, Levothyroxine
- Where
- 139 sites in United States, Puerto Rico
- Volunteers
- 2,701 people
- Sponsor
- AbbVie
Healthy Volunteer
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
- Trial name
- NCT06953934
- Testing
- ABBV-932
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AbbVie
Ovarian Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab…
- Trial name
- FLORENZA (NCT07059845)
- Testing
- Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- SEZanne (NCT07155174)
- Testing
- ABBV-706, Atezolizumab, Etoposide
- Where
- 69 sites in United States, Belgium and 11 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Ovarian Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
- Trial name
- NCT07278336
- Testing
- ABBV-901, Bevacizumab, Carboplatin
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 285 people
- Sponsor
- AbbVie
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07490301
- Testing
- Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 900 people
- Sponsor
- AbbVie
Healthy Volunteer
Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.
- Trial name
- NCT07680686
- Testing
- Ubrogepant
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AbbVie
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07769502
- Testing
- Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other…
- Trial name
- NCT06810505
- Testing
- Atogepant
- Where
- 66 sites in United States, Canada and 9 more
- Volunteers
- 420 people
- Sponsor
- AbbVie
Primary Open Angle Glaucoma
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab…
- Trial name
- NCT06822738
- Testing
- XEN63 Glaucoma Treatment System
- Where
- 29 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Colorectal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care…
- Trial name
- NCT07023289
- Testing
- Telisotuzumab Adizutecan, Standard of Care
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 140 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for…
- Trial name
- NCT06972446
- Testing
- Lutikizumab, Ravagalimab
- Where
- 96 sites in United States, Canada and 10 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Jawline and Neck Appearance
Study to Assess Participant Satisfaction After Jawline and Neck Treatment
The goal of this study is to evaluate overall participant satisfaction with the jawline and neck. Participants will receive select Juvéderm products and onabotulinumtoxinA in the jaw area and neck per eligibility criteria.
- Trial name
- AURA (NCT07794891)
- Testing
- OnabotulinumtoxinA, SKINVIVE, VOLUX
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Diffuse Large B-Cell Lymphoma
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma.
- Trial name
- NCT07862764
- Volunteers
- 175 people
- Sponsor
- AbbVie
Episodic Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- NCT05711394
- Testing
- Atogepant
- Where
- 98 sites in United States, Belgium and 14 more
- Volunteers
- 450 people
- Sponsor
- AbbVie
Forehead Lines
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
The objective of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of moderate to severe forehead lines (FHL) in adult participants.
- Trial name
- NCT07730554
- Testing
- AGN-151586
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- AbbVie